Orthofix Announces New Term Loan
Orthofix Medical (NASDAQ:OFIX) has secured a new $275 million senior-secured term loan with Oxford Finance , featuring a 48-month interest-only period. The initial $160 million will retire existing credit facilities, while the remaining $115 million will be available after January 2025. Of this amount, $65 million will be accessible at borrower's option through June 2026, and $50 million at lender's discretion through January 2029. The company reports significant improvements in adjusted EBITDA and achieving free cash flow positive status in 2024, supporting their strategy for long-term profitable growth.
Orthofix Medical (NASDAQ:OFIX) ha ottenuto un nuovo prestito term loan senior garantito di 275 milioni di dollari con Oxford Finance, che prevede un periodo di soli interessi di 48 mesi. I primi 160 milioni saranno utilizzati per estinguere le linee di credito esistenti, mentre i restanti 115 milioni saranno disponibili dopo gennaio 2025. Di questa somma, 65 milioni saranno accessibili a scelta del mutuatario fino a giugno 2026 e 50 milioni a discrezione del creditore fino a gennaio 2029. L'azienda riporta significativi miglioramenti nell'EBITDA rettificato e prevede di raggiungere uno stato di flusso di cassa positivo nel 2024, supportando la propria strategia per una crescita redditizia a lungo termine.
Orthofix Medical (NASDAQ:OFIX) ha conseguido un nuevo préstamo a plazo senior garantizado de 275 millones de dólares con Oxford Finance, que incluye un período de solo intereses de 48 meses. Los primeros 160 millones se utilizarán para saldar las líneas de crédito existentes, mientras que los 115 millones restantes estarán disponibles después de enero de 2025. De esta cantidad, 65 millones serán accesibles a opción del prestatario hasta junio de 2026 y 50 millones a discreción del prestamista hasta enero de 2029. La empresa informa de mejoras significativas en el EBITDA ajustado y prevé alcanzar un flujo de caja libre positivo en 2024, respaldando su estrategia para un crecimiento rentable a largo plazo.
Orthofix Medical (NASDAQ:OFIX)는 Oxford Finance와 함께 2억7500만 달러 규모의 새로운 우선 담보 대출을 확보하였으며, 48개월의 이자 전액 지불 기간이 포함되어 있습니다. 최초의 1억6000만 달러는 기존의 신용 시설을 상환하는 데 사용될 것이며, 나머지 1억1500만 달러는 2025년 1월 이후에 사용할 수 있습니다. 이 중 6500만 달러는 차용자의 선택에 따라 2026년 6월까지 접근할 수 있고, 5000만 달러는 대출자의 재량에 따라 2029년 1월까지 접근할 수 있습니다. 회사는 조정된 EBITDA의 상당한 개선을 보고하고 있으며, 2024년에 자유 현금 흐름이 긍정적으로 전환될 것으로 예상하여, 장기적인 수익성 있는 성장 전략을 지원하고 있습니다.
Orthofix Medical (NASDAQ:OFIX) a sécurisé un nouveau prêt senior garanti de 275 millions de dollars avec Oxford Finance, comprenant une période de 48 mois d'intérêts uniquement. Les premiers 160 millions seront utilisés pour rembourser des facilités de crédit existantes, tandis que les 115 millions restants seront disponibles après janvier 2025. Sur ce montant, 65 millions seront accessibles à la demande de l'emprunteur jusqu'en juin 2026, et 50 millions à la discrétion du prêteur jusqu'en janvier 2029. L'entreprise signale des améliorations significatives de l'EBITDA ajusté et prévoit d'atteindre un flux de trésorerie libre positif en 2024, soutenant ainsi sa stratégie de croissance rentable à long terme.
Orthofix Medical (NASDAQ:OFIX) hat einen neuen gesicherten Senior-Darlehen über 275 Millionen US-Dollar mit Oxford Finance abgeschlossen, das eine 48-monatige Zinszahlungsperiode umfasst. Die ersten 160 Millionen werden zur Rückzahlung bestehender Kreditlinien verwendet, während die verbleibenden 115 Millionen nach Januar 2025 verfügbar sein werden. Von diesem Betrag werden 65 Millionen bis Juni 2026 auf Wunsch des Kreditnehmers zugänglich sein und 50 Millionen nach Ermessen des Kreditgebers bis Januar 2029. Das Unternehmen berichtet von erheblichen Verbesserungen beim bereinigten EBITDA und erwartet, 2024 einen positiven Cashflow zu erreichen, was ihre Strategie für ein langfristig profitables Wachstum unterstützt.
- Secured $275M non-dilutive financing with favorable terms
- Achieved free cash flow positive status in 2024
- Reported significant improvements in adjusted EBITDA
- Extended payment flexibility with 48-month interest-only period
- Increased debt burden with new $275M term loan
- $50M of the facility is subject to lender's discretion
Insights
This new
The company's improved financial metrics, particularly becoming free cash flow positive and showing better adjusted EBITDA, likely helped secure more favorable loan terms. The non-dilutive nature of this financing preserves shareholder value compared to equity-based alternatives. The structure, with
New Financing Replaces Existing Term Loan and Seeks to Further Optimize the Company’s Capital Structure to Support Long-Term, Profitable Growth
Under the terms of the new loan,
“The completion of this refinancing initiative is an important step in Orthofix’s trajectory and provides us with more favorable terms under which we can continue to invest in the growth and evolution of the Company,” said Julie Andrews, Chief Financial Officer. “Our performance to date in 2024 has been characterized by steady financial improvements throughout the year, including significant progress in adjusted EBITDA and becoming free cash flow positive, both of which underpin our confidence in our ability to drive long-term profitable growth.”
Massimo Calafiore, President and Chief Executive Officer, added, “On the heels of our strong third quarter, it’s clear that Orthofix’s focus on executing a clear strategy for profitable growth is delivering compelling results. Through our focus on bringing to market a comprehensive portfolio of transformative solutions and delivering unmatched customer service, which collectively are helping us drive more profitable sales, we have significantly improved our operating and financial position and paved the way for sustainable growth. As we look to 2025 and beyond, we plan to build on our progress by further sharpening our commercial focus, operating with discipline for margin expansion and ensuring we are best positioned to create value for our shareholders over the long term.”
The lending group includes Oxford Finance and K2 HealthVentures.
“We are proud to partner with Orthofix as they advance their mission to enhance mobility and improve quality of life for patients worldwide," said Garrett Henn, Managing Director and Co-Head of Enterprise Lending at Oxford. "Our partnership underscores our confidence in Orthofix’s experienced leadership team and their strategy to drive sustainable, long-term growth and profitability.”
Further details regarding the new debt facility agreement are included in the Company’s Form 10-Q filed with the
About Orthofix
Orthofix is a global medical technology company headquartered in
About Oxford Finance LLC
Oxford Finance LLC is a specialty finance firm providing senior secured loans to public and private life sciences, healthcare services, healthtech, business services and SaaS companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to over 700 companies, allowing borrowers to maximize their equity by leveraging their assets. Since 2002, Oxford has originated more than
Forward-Looking Statements
This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology. Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024, as well as any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K filed with the SEC. The Company’s public filings with the SEC are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107942519/en/
Investor Relations
Julie Dewey
JulieDewey@Orthofix.com
209.613.6945
Media Relations
Denise Landry
DeniseLandry@Orthofix.com
214.937.2529
Source: Orthofix Medical Inc.
FAQ
What is the size of Orthofix's (OFIX) new term loan announced in 2024?
How much of Orthofix's (OFIX) new term loan will be funded upfront?
When will the remaining $115M of Orthofix's (OFIX) term loan become available?